ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and treatment"

  • Abstract Number: 1736 • 2017 ACR/ARHP Annual Meeting

    Deep Immunophenotyping of T-Lymphocytes with a 37-Channel Mass Cytometry (CyTOF) Panel for the Identification of Pathological Cell Functions and the Prediction of Response to Biologic Drugs in Rheumatoid Arthritis

    Ben Mulhearn1,2,3, Darren Plant2, Ann W. Morgan4,5, Anthony G. Wilson6, John D Isaacs7,8, Jane Worthington9, Soumya Raychaudhuri9,10,11,12, Tracy Hussell1, Anne Barton13,14 and Sebastien Viatte2, 1Manchester Collaborative Centre for Inflammation Research, University of Manchester, Manchester, United Kingdom, 2The University of Manchester, Arthritis Research UK Centre for Genetics and Genomics, , Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Medicine, Biology and Health, Manchester, United Kingdom, 3Kellgren Centre for Rheumatology, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 4Section of Musculoskeletal Disease, NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, 5Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 6UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland, 7Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, United Kingdom, 8National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, 9Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 10Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 11Program in Medical and Population Genetics, Broad Institute of Massachusetts Technical Institute, Harvard University, Cambridge, MA, 12Partners Center for Personalized Genetic Medicine, Boston, MA, 13Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK, Manchester, United Kingdom, 14The Kellgren Centre for Rheumatology, Central Manchester Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom

    Background/Purpose: Pathogenic immune cell types and functions have not been identified yet in rheumatoid arthritis (RA). This is explained by the impact of disease heterogeneity…
  • Abstract Number: 363 • 2017 ACR/ARHP Annual Meeting

    Work Productivity Benefit in Patients with Rheumatoid Arthritis Initiating Etanercept in the United States

    Mahdi Gharaibeh1, Bradley S. Stolshek2, Alex Mutebi3, Amy M. Sainski-Nguyen4, David Collier5 and Emily Durden4, 1Amgen Inc., Thousand Oaks, CA, 2Amgen, Inc., Thousand Oaks, CA, 3Amgen, Thousand Oaks, CA, 4Truven Health Analytics, Ann Arbor, MI, 5Amgen, Inc, Terni, Italy

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that can progress to joint destruction, functional impairment and disability that can lead to work productivity…
  • Abstract Number: 1904 • 2017 ACR/ARHP Annual Meeting

    A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Upadacitinib (ABT-494), a Selective JAK-1 Inhibitor, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Dmards

    Gerd R. Burmester1, Joel Kremer2, Filip van Den Bosch3, Yihan Li4, Yijie Zhou4, Ahmed A. Othman5, Aileen L. Pangan4 and Heidi S. Camp5, 1Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, 2Albany Medical College, Albany, NY, 3Rheumatology, Ghent University Hospital, Gent, Belgium, 4AbbVie Inc., North Chicago, IL, 5AbbVie, North Chicago, IL

    Background/Purpose: Upadacitinib (UPA) is an oral, selective JAK-1 inhibitor in development for the treatment of patients (pts) with moderate to severe rheumatoid arthritis (RA) and…
  • Abstract Number: 1618 • 2016 ACR/ARHP Annual Meeting

    Leflunomide, Sulfasalazine and Hydroxychloroquine for Rheumatoid Arthritis: Efficacious but Poorly Tolerated

    Kyle A. Register1, Amy C. Cannella2, Ted R. Mikuls3 and James R. O'Dell4, 1Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 2Section of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: The combination of methotrexate (MTX), sulfasalazine (SSZ) and hydroxychloroquine (HCQ) (triple therapy) is a highly effective and well-tolerated treatment in rheumatoid arthritis (RA). While…
  • Abstract Number: 1619 • 2016 ACR/ARHP Annual Meeting

    EARTH EXPLORER 2, a Phase IIb Exploratory Study Evaluating Efficacy and Safety of Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, and the Tumor Necrosis Factor Antagonist Golimumab in Rheumatoid Arthritis

    Michael Weinblatt1, IB McInnes2, JM Kremer3, P Miranda4, J Vencovský5, A Godwood6, M Albulescu6, D Close^6 and GR Burmester^7, 1Brigham and Women’s Hospital, Boston, MA, 2University of Glasgow, Glasgow, United Kingdom, 3The Albany Medical College, Albany, NY, 4Centro De Estudios Reumatológicos, Santiago, Chile, 5Charles University, Prague, Czech Republic, 6MedImmune, Cambridge, United Kingdom, 7Charité – University Medicine Berlin, Berlin, Germany

    Background/Purpose: Mavrilimumab, a fully human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor receptor-α, has demonstrated efficacy and safety in disease-modifying antirheumatic drug (DMARD)-inadequate responder (IR)…
  • Abstract Number: 1640 • 2016 ACR/ARHP Annual Meeting

    Effect of BMI on Baricitinib Efficacy: Pooled Analysis from Two Phase 3 Rheumatoid Arthritis Clinical Trials

    Cristiano A.F Zerbini1, David Muram2, Vipin K. Arora2, Jahangir Alam2 and Jeffrey R. Curtis3, 1Centro Paulista de Investigação Clinica, São Paulo, Brazil, 2Eli Lilly and Company, Indianapolis, IN, 3Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose : The efficacy of some rheumatoid arthritis (RA) therapies is reduced among patients with high BMI. This analysis assessed the effects of baseline BMI…
  • Abstract Number: 1676 • 2016 ACR/ARHP Annual Meeting

    Methotrexate and Anti-Tumor Necrosis Treatment Improve Endothelial Function in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

    Gia Deyab1, Ingrid Hokstad2, Stefan Agewall3, Torstein Lyberg4, Jon Elling Whist5, Milada Cvancarova Småstuen6, Gunnbjørg Hjeltnes7 and Ivana Hollan8,9,10,11, 1Department of Medical Biochemistry, Innlandet Hospital Trust, Lillehammer, Norway, 2Lillehammer Hospitat for Rheumatic Diseases, Lillehammer, Norway, 3University of Oslo, Oslo, Norway, 4Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, 5Innlandet Hospital Trust, Lillehammer, Norway, 6Institution of health care - Health science PhD program, Oslo and Akershus University College, Oslo, Norway, 7Medicine, Innlandet Hospital Trust, Lillehammer, Norway, 8Harvard Medical School, Boston, MA, 9Department of Medicine, Brigham and Women's Hospital, Boston, MA, 10Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 11Innlandet Hospital Trust, Brumunddal, Norway

    Background/Purpose: Inflammatory rheumatic diseases (IRDs) are associated with accelerated atherosclerosis, which progression is related to inflammation (1). One of the first stages in atherogenesis is…
  • Abstract Number: 2240 • 2016 ACR/ARHP Annual Meeting

    A Descriptive Analysis of Real-World Treatment Patterns in a Turkish Rheumatology Population That Continued Innovator Infliximab (Remicade) Therapy or Switched to Biosimilar Infliximab

    Yusuf Yazici1, Lin Xie2, Adesuwa Ogbomo3, Dennis Parenti4, Kavitha Goyal4, Amanda Teeple4, Lorie A. Ellis5 and Ismail Simsek6, 1New York University, Hospital of Joint Diseases, New York, NY, 2Director, Health Economics & Outcomes Research, STATinMED Research, Ann Arbor, MI, 3STATinMED Research Inc., Ann Arbor, MI, 4Janssen Scientific Affairs, LLC, Horsham, PA, 5Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, 6Guven Hospital, Ankara, Turkey

    Background/Purpose: This study examined treatment patterns in a rheumatology patient (pt) population initially prescribed innovator infliximab (IFX) that either switched to biosimilar infliximab (CT-P13) or…
  • Abstract Number: 2479 • 2016 ACR/ARHP Annual Meeting

    Work Productivity in Early Rheumatoid Arthritis Patients Treated before and after Implementation of a Treat-to-Target Strategy

    Siri Lillegraven1, Maria Dahl Mjaavatten1, Nina P. Sundlisater1, Anna-Birgitte Aga1, Inge C Olsen2, Till Uhlig1, Daniel H. Solomon3, Tore K Kvien1, Espen A. Haavardsholm1 and the ARCTIC Study Group, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) is a known cause of work productivity loss. Participation in work-related activities is defined as part of the primary goal of…
  • Abstract Number: 2494 • 2016 ACR/ARHP Annual Meeting

    The Effect of Body Mass on DAS28 Response in Patients with Rheumatoid Arthritis Treated with Abatacept

    J Fransen1, L Tweehuysen2, A den Broeder3, R Postema4, E Alemao5 and F van den Hoogen6, 1Department of Rheumatolgy, Radboud UMC, Nijmegen, Netherlands, 2Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, 3Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 4Bristol-Myers Squibb, Uxbridge, United Kingdom, 5Bristol-Myers Squibb, Princeton, NJ, 6Rheumatology, Radboud UMC, Nijmegen, Netherlands

    Background/Purpose: Abatacept is an effective biologic agent indicated for the treatment of RA.1 Recent studies have indicated that obesity and being overweight could reduce the…
  • Abstract Number: 2536 • 2016 ACR/ARHP Annual Meeting

    The Performance of a Single Centre Interventional Clinic in Early Rheumatoid Arthritis

    Rok Jese1, Ales Ambrozic2, Natasa Gaspersic2, Alojzija Hocevar1, Boris Lestan1, Milena Pavic Nikolic1, Martina Plešivčnik Novljan2, Sonja Praprotnik3, Ziga Rotar1, Alenka Šipek Dolničar1, Dasa Suput Skvarca1 and Matija Tomsic1, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia, 3Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia

    Background/Purpose:  In early rheumatoid arthritis (RA), first assessment by a rheumatologist and/or initiation of disease-modifying anti-rheumatic drugs (DMARD) within 12 weeks of symptom onset are…
  • Abstract Number: 2635 • 2016 ACR/ARHP Annual Meeting

    Using Patient Reported Outcomes to Inform a Treat to Target Treatment Approach in RA

    Eric M. Ruderman1, Jennifer Beaumont2, Emily Bacalao1, George J. Greene2, Azra Muftic2 and David Cella2, 1Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: The Patient Reported Outcomes Measurement Information System (PROMIS) is an NIH initiative to develop patient-reported outcome measures (PROs) for use across chronic conditions. PROMIS…
  • Abstract Number: 2636 • 2016 ACR/ARHP Annual Meeting

    No Strong Evidence Supporting Predictors for Successful Dose Reduction or Discontinuation of a Biologic in Rheumatoid Arthritis: A Systematic Review

    L. Tweehuysen1, C.H. van den Ende2, F.M.M. Beeren2, E.M.J. Been2, F.H.J. van den Hoogen3,4 and A.A. den Broeder3, 1Sint Maartenskliniek, Nijmegen, Netherlands, 2Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 3Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 4Rheumatology, Radboudumc, Nijmegen, Netherlands

    Background/Purpose: Tapering of biologics in rheumatoid arthritis (RA) is based on a trial-and-error disease activity guided strategy, because it is not known in advance which…
  • Abstract Number: 2649 • 2016 ACR/ARHP Annual Meeting

    Patient Preferences Regarding Rheumatoid Arthritis Therapies in Lebanon: Results from a National, Multicenter, Cross-Sectional Survey

    Fouad Fayad1, Nelly Ziade2, Georges Merheb3,4, Said Attoui5, Alla Aiko6, Kamel Mroue5 and Abdel Fattah Masri7, 1Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, 2Rheumatology, Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, 3Internal Medicine, Notre Dame des Secours University Hospital, Jbeil, Lebanon, 4Holly Spirit University, Kaslik, Lebanon, 5Hammoud University Medical Center, Saida, Lebanon, 6Saint Georges Hospital, Beirut, Lebanon, 7American University of Beirut Medical Center, Beirut, Lebanon

    Background/Purpose: Treatment options in rheumatoid arthritis (RA) have expanded significantly over recent years, and several agents are now available for oral, subcutaneous (SC) or intravenous…
  • Abstract Number: 607 • 2016 ACR/ARHP Annual Meeting

    The Clinical Response to Biologic and Non-Biologic Disease Modifying Antirheumatic Drugs (DMARDs) According to Gender in a French-Canadian Population with Rheumatoid Arthritis (RA)

    Sonia Lagacé1, Louis Bessette2,3, Louis Coupal4 and Denis Choquette4, 1Medicine, Laval University, Quebec, QC, Canada, 2Rheumatology, Laval University, Québec, QC, Canada, 3Rhumatologie, CHU de Québec - Université Laval, Quebec, QC, Canada, 4Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada

    Background/Purpose: Several studies have reported that women with RA had higher level of pain, disease activity and functional impairment compared to men. In addition, women…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology